Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension studyHeinz Gisslinger, Jiřı́ Schwarz, Liana Gercheva et al.|The Lancet Haematology|2020Cited by 351
Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study ResultsHeinz Gisslinger, Christoph Klade, Veronika Buxhofer‐Ausch et al.|Blood|2018Cited by 18